Arcus Biosciences (NYSE:RCUS) Given Neutral Rating at HC Wainwright

Arcus Biosciences (NYSE:RCUS)‘s stock had its “neutral” rating reiterated by investment analysts at HC Wainwright in a report issued on Wednesday, Benzinga reports. They presently have a $20.00 price objective on the stock. HC Wainwright’s price target would indicate a potential upside of 30.80% from the company’s current price.

Several other equities analysts also recently weighed in on RCUS. Wedbush reissued an “outperform” rating and set a $30.00 target price on shares of Arcus Biosciences in a research report on Thursday, October 3rd. Evercore ISI upgraded Arcus Biosciences to a “strong-buy” rating in a research report on Friday, August 9th. Wells Fargo & Company assumed coverage on shares of Arcus Biosciences in a research note on Tuesday, October 8th. They set an “overweight” rating and a $29.00 target price for the company. Barclays raised their price target on shares of Arcus Biosciences from $25.00 to $29.00 and gave the stock an “overweight” rating in a research note on Friday, October 25th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Arcus Biosciences in a report on Thursday, October 3rd. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $33.67.

Arcus Biosciences Trading Down 1.7 %

NYSE RCUS opened at $15.29 on Wednesday. Arcus Biosciences has a 12 month low of $12.95 and a 12 month high of $20.31. The stock has a market cap of $1.40 billion, a PE ratio of -4.95 and a beta of 0.89. The stock’s 50 day moving average is $16.64 and its 200 day moving average is $16.03.

Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings data on Thursday, August 8th. The company reported ($1.02) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($1.02). Arcus Biosciences had a negative return on equity of 42.86% and a negative net margin of 100.81%. The business had revenue of $39.00 million for the quarter, compared to the consensus estimate of $26.24 million. During the same quarter in the previous year, the company posted ($1.04) EPS. The company’s revenue was up 34.5% compared to the same quarter last year. On average, analysts forecast that Arcus Biosciences will post -3.25 EPS for the current fiscal year.

Hedge Funds Weigh In On Arcus Biosciences

A number of large investors have recently made changes to their positions in the business. Headlands Technologies LLC purchased a new stake in shares of Arcus Biosciences during the first quarter worth about $59,000. Innealta Capital LLC acquired a new stake in Arcus Biosciences during the 2nd quarter worth about $66,000. Point72 DIFC Ltd purchased a new stake in Arcus Biosciences during the 2nd quarter valued at about $83,000. ProShare Advisors LLC increased its holdings in shares of Arcus Biosciences by 7.4% in the first quarter. ProShare Advisors LLC now owns 10,846 shares of the company’s stock valued at $205,000 after purchasing an additional 746 shares during the period. Finally, Diversified Trust Co raised its stake in shares of Arcus Biosciences by 12.1% in the second quarter. Diversified Trust Co now owns 13,545 shares of the company’s stock worth $206,000 after purchasing an additional 1,467 shares during the last quarter. 92.89% of the stock is owned by institutional investors and hedge funds.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.